clinical trial · NCT05695391
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
Laboratoire français de Fractionnement et de Biotechnologies·phase3·terminated·n = 2
HemophiliaCoagulation Factor VIIa (Recombinant)
brief summary
This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures.
started
Jun 7, 2024
primary completion
Jun 1, 2025
completion
Jun 1, 2025
last updated
Jul 9, 2025
official title
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol